TPTerence J. Purdon

Terence J. Purdon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Terence J. Purdon has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplemental Figure 1 from Augmenting CAR T-cell Functions with LIGHT

    by Winson Cai, Kento Tanaka, Xiaoli Mi, Vinagolu K. Rajasekhar, Jonathan F. Khan, Sarah Yoo, Elisa de Stanchina, Jahan Rahman, Serena Mathew, Parwiz Abrahimi, et al.

    (A) Transgene expression of the CAR constructs after retroviral transduction of human T cells by flow cytometry. CD19 CAR T cells were used as irrelevant CAR T cell control. (B-D) Healthy human donor-derived mesothelin-targeted CAR T cells were cocultured with tumor cells expressing GFP and firefly luciferase at different effector to tumor ratios. Bioluminescence was measured 72 hours later and plotted as a percentage of the signal detected with tumor cells alone (max bioluminescence signal). Associated expression of mesothelin with the corresponding mesothelin-positive cell lines are shown. JMN (left), SW620 (middle), and MDA-MB-231 (right). Plots represent 3 independent experiments. Data errors were analyzed with mean ± SEM. (E) HVEM expression in PDAC cell lines (CAPAN2, AsPC1, BxPC3, Panc1) (F) Flow cytometric analysis of overexpression constructs derived from Panc1 wildtype. Panc1 Mesothelin overexpression, Panc1 LTβR overexpression, and Panc1 Mesothelin and LTβR Overexpression

  • Open Access

    Supplemental Figure 4 from Augmenting CAR T-cell Functions with LIGHT

    by Winson Cai, Kento Tanaka, Xiaoli Mi, Vinagolu K. Rajasekhar, Jonathan F. Khan, Sarah Yoo, Elisa de Stanchina, Jahan Rahman, Serena Mathew, Parwiz Abrahimi, et al.

    (A) Violin plots showing quality metrics of single cells included in downstream analysis. nCount RNA: number of RNA unique molecular identifiers (UMI); nFeature RNA: number of detected genes; nCount_ADT: number of antibody UMI; nFeature_ADT: number of detected antibodies; percent.mt: percentage of mitochondrial gene expression; HTO_margin: difference between signals for the hashtag with the highest signal and the hashtag with the second highest signal. (B) (C) Weighted-nearest neighbor (WNN) UMAP of single cells colored by condition (CAR T cell construct and timepoint) (top) and CD4+ vs CD8+ cell type (bottom). Expression of T cell markers (CD3, CD4, and CD8) at the RNA (top) and antibody-derived tag (ADT) level projected on WNN UMAPs. (D) Expression of the RNA (top) and ADT (bottom) markers of T cell type, proliferation, activation, cytotoxicity, and cytokines support CITE-seq cluster annotation. Blue is control CAR T cell and Red is LIGHT-CAR T cell.

  • Open Access

    Supplemental Figure 2 from Augmenting CAR T-cell Functions with LIGHT

    by Winson Cai, Kento Tanaka, Xiaoli Mi, Vinagolu K. Rajasekhar, Jonathan F. Khan, Sarah Yoo, Elisa de Stanchina, Jahan Rahman, Serena Mathew, Parwiz Abrahimi, et al.

    (A) ELISA quantification of soluble LIGHT in cell culture media after 24 hours of incubation. (B) Supernatant from LIGHT-CAR T cells and second-generation CAR T cells were added to corresponding CAR T cells and in vitro cytolysis was assessed against AsPC1. Data is representative of 2 independent experiments from two different T cell donors. (C) Supernatant from LIGHT-CAR T cells and second-generation CAR T cells were added to corresponding CAR T cells and in vitro cytolysis was assessed against MIAPACA2. Data is representative of 2 independent experiments from two different T cell donors. (D) Cytotoxicity assay with various mesothelin-directed CAR constructs and the addition of recombinant LIGHT to MIAPACA2. Data is representative of 3 independent experiments from two different T cell donors. (E) Mesothelin-directed LIGHT-CAR T cells exhibited similar proliferation in a repetitive antigen stimulation assay with moderately high mesothelin expression PDAC cell line, AsPC1. CAR T cells were cocultured with tumor cells at a 4:1 effector: tumor ratio for 5 days, and then CAR T cells were taken out and put onto new tumor cells at the original E:T ratio. The total fold expansion was quantified from multiplying each round of fold expansion every 5 days. Data is representative of 3 independent experiments of 3 different human donors and data errors were analyzed with mean ± SEM.

  • Open Access

    Supplemental Fig. 7 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models

    by Mackenzie M. Lieberman, Jason H. Tong, Nkechi U. Odukwe, Colin A. Chavel, Gina G. Bishara, Kimberly M. Crasti, Megan M. Herr, Payal Goala, Terence J. Purdon, Rebecca Burchett, et al.

    CD86 expression on patient MM cells prior to CAR T therapy.

  • Open Access

    Supplemental Fig. 3 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models

    by Mackenzie M. Lieberman, Jason H. Tong, Nkechi U. Odukwe, Colin A. Chavel, Gina G. Bishara, Kimberly M. Crasti, Megan M. Herr, Payal Goala, Terence J. Purdon, Rebecca Burchett, et al.

    Characterization of CAR T cell mitochondrial metabolism.

  • Open Access

    Supplemental Figure 5 from Augmenting CAR T-cell Functions with LIGHT

    by Winson Cai, Kento Tanaka, Xiaoli Mi, Vinagolu K. Rajasekhar, Jonathan F. Khan, Sarah Yoo, Elisa de Stanchina, Jahan Rahman, Serena Mathew, Parwiz Abrahimi, et al.

    (A) CAR T cells infiltration and expression of LIGHT at the tumor site was quantified by flow cytometric analysis on day 14 post CAR T cell treatment. (B) (C) Quantification of CAR T cells per gram of AsPC1 tumor mass on day 14 post CAR T cell treatment. Plot is representative of 4 to 5 mice per treatment group. Immunohistochemistry staining of mesothelin-negative cancer cell line, Panc1. Negative control. (D) Immunohistochemistry staining of mesothelin-positive cancer cell line, MDA-MB-231. Positive control. (E) Immunohistochemistry staining of various PDX slides samples to validate their mesothelin expression. (F) Flow cytometric analysis of mesothelin expression in PDAC2, one of the PDX selected for in vivo model. (G) In vitro cytotoxicity assay of PDX PDAC2 cocultured with various CAR T cell constructs. Plot represents 2 independent experiments of separate donor T cells.

  • Open Access

    Supplemental Figure 3 from Augmenting CAR T-cell Functions with LIGHT

    by Winson Cai, Kento Tanaka, Xiaoli Mi, Vinagolu K. Rajasekhar, Jonathan F. Khan, Sarah Yoo, Elisa de Stanchina, Jahan Rahman, Serena Mathew, Parwiz Abrahimi, et al.

    (A) Flow cytometric analysis of LTβR expression of MIAPACA2 cells after CRISPR knockout (KO). MIAPACA2 LTβR KO cells were also transduced with non-signaling LTβR without intracellular signaling portion (tLTBR). (B) MIAPACA2 LTβR KO healthy human donor-derived mesothelin-targeted CAR T cells were cocultured with tumor cells expressing GFP and firefly luciferase at different effector to tumor ratios. Bioluminescence was measured 72 hours later and plotted as a percentage of the signal detected in a coculture of non-functional Meso-DEL-CAR T cells. Plots represent 3 independent experiments. Data errors were analyzed with mean ± SEM. (C) No killing advantage was observed with LIGHT CAR T cells co-cultured with the MIAPACA2 non-signaling, (truncated) tLTβR cancer cell line. (D) Cytotoxicity assay of MIAPACA2 and MIAPACA2 LTβR KO cell lines with non-functional CAR T cells (Meso-DEL and Meso-DEL-LIGHT). CAR T cells have been activated by CD3/CD28 Dynabeads for 1 day prior to adding cancer cells at 4 to 1 effector to tumor (E:T) ratio for 48 hours. Plots represent 3 independent experiments from 3 different donor T cells. Data errors were analyzed with mean ± SEM. (E) (F) Flow cytometric analysis of HVEM expression of CAR T cells before and after CRISPR KO. (red) represents isotype control, (blue) represents wild type CAR T cell expression, and (orange) represents the HVEM expression after CRISPR KO in CAR T cells. HVEM KO CAR T cells were cocultured with moderately high mesothelin expression AsPC1 tumor cells expressing GFP and firefly luciferase at different effector to tumor ratios. Bioluminescence was measured 48 hours later and plotted as a percentage of the signal detected in tumor alone. Plots represent 2 independent experiments from 2 healthy donor T cells. Data errors were analyzed with mean ± SEM. (G) HVEM KO CAR T cells were cocultured with low mesothelin expression MIAPACA2 tumor cells expressing GFP and firefly luciferase at different effector to tumor ratios. Bioluminescence was measured 48 hours later and plotted as a percentage of the signal detected in tumor alone. Plots represent 2 independent experiments from 2 healthy donor T cells. Data errors were analyzed with mean ± SEM. (H) Protein array analysis of 35 apoptosis-related proteins in MIAPACA2 cells treated with Meso-DEL, Meso-28z, and Meso28z-LIGHT. Representative array images indicating the protein levels of various apoptosis-related proteins in MIAPACA2 after 48 hours of coculture with CAR T cells at 4:1 E:T ratio. (I) (J) The relative fold change of the apoptosis-related proteins in MIAPACA2 treated with various conditions of CAR T cells was normalized to Meso-DEL (control). Most differentially expressed proteins in MIAPACA2 between Meso-28z and Meso-28z-LIGHT CAR T cells treated group.

  • Open Access

    Key Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models

    by Mackenzie M. Lieberman, Jason H. Tong, Nkechi U. Odukwe, Colin A. Chavel, Gina G. Bishara, Kimberly M. Crasti, Megan M. Herr, Payal Goala, Terence J. Purdon, Rebecca Burchett, et al.

    Key Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models

  • Open Access

    Supplemental Fig. 8 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models

    by Mackenzie M. Lieberman, Jason H. Tong, Nkechi U. Odukwe, Colin A. Chavel, Gina G. Bishara, Kimberly M. Crasti, Megan M. Herr, Payal Goala, Terence J. Purdon, Rebecca Burchett, et al.

    Effect of transient abatacept exposure on MM.1S growth.

  • Open Access

    Supplemental Figure 6 from Augmenting CAR T-cell Functions with LIGHT

    by Winson Cai, Kento Tanaka, Xiaoli Mi, Vinagolu K. Rajasekhar, Jonathan F. Khan, Sarah Yoo, Elisa de Stanchina, Jahan Rahman, Serena Mathew, Parwiz Abrahimi, et al.

    (A) Histopathological analysis images of certain organs in the 3 CAR-treated groups following full necropsy on day 30. Representative regions displaying lesion or absence of lesion at 20magnification are stained with H&E. Scale bar 100 microns. (B) Histologic examination of various organs and tissues on day 30 after CAR T cell treatment. (C) Serum chemistry values of mice on day 30 after CAR T cell treatment. Red represents higher than reference range and blue represents lower than reference range.